The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

aragonpharm.com

Stage

Acquired

Total Raised

$122M

Investors Count

6

Deal Terms

5

Portfolio Exits

1

Aragon Pharmaceuticals Funding, Aragon Pharmaceuticals Valuation & Aragon Pharmaceuticals Revenue

5 Fundings

Aragon Pharmaceuticals's latest funding round was a Acquired for on August 19, 2013.

Aragon Pharmaceuticals's valuation in April 2010 was $74.91M.

Aragon Pharmaceuticals's latest post-money valuation is from August 2013.

Sign up for a free trial to see Aragon Pharmaceuticals's valuations in August 2013 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

8/19/2013

Acquired

$99M

0

FY undefined

2

10/4/2012

Series D

$99M

0

FY undefined

10

3/6/2012

Series C

$99M

0

FY undefined

10

4/22/2010

Series B

$99M

$74.91M

0

FY undefined

0

5/15/2009

Series A

$99M

0

FY undefined

0

Date

8/19/2013

10/4/2012

3/6/2012

4/22/2010

5/15/2009

Round

Acquired

Series D

Series C

Series B

Series A

Amount

$99M

$99M

$99M

$99M

Investors

Valuation

$99M

$74.91M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

2

10

10

0

0

Aragon Pharmaceuticals Deal Terms

5 Deal Terms

Aragon Pharmaceuticals's deal structure is available for 5 funding rounds, including their Acquired from August 19, 2013.

Round

Acquired

Series D

Series C

Series B

Series A

Funding Date

$99M

$99M

$99M

$99M

$99M

Pre-Money Valuation

Post-Money Valuation

$99M

Amount Raised

$99M

$99M

$99M

$99M

Shares Authorized

Issuance Price

$99M

$99M

Dividend Rate

$99M

$99M

Liquidation Preferences

$99M

$99M

Liquidation Price

Participation

Conversion Price

Anti Dilution

$99M

$99M

General Voting

$99M

$99M

$99M

$99M

$99M

Board Voting

$99M

$99M

$99M

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Acquired

$99M

$99M

$99M

$99M

Series D

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series C

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series B

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

Aragon Pharmaceuticals Investors

6 Investors

Aragon Pharmaceuticals has 6 investors. Johnson & Johnson invested in Aragon Pharmaceuticals's Acquired funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

8/19/2013

8/19/2013

1
Acquired

Corporation

New Jersey

00/00/0000

00/00/0000

OrbiMed Advisors

Subscribe to see more

Venture Capital

New York

00/00/0000

00/00/0000

The Column Group

Subscribe to see more

Venture Capital

California

00/00/0000

00/00/0000

Aisling Capital

Subscribe to see more

Subscribe to see more

Private Equity

New York

00/00/0000

00/00/0000

Topspin Consumer Partners

Subscribe to see more

Private Equity

New York

First funding

8/19/2013

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

8/19/2013

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

OrbiMed Advisors

The Column Group

Aisling Capital

Topspin Consumer Partners

Rounds

1
Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Subscribe to see more

Type

Corporation

Venture Capital

Venture Capital

Private Equity

Private Equity

Location

New Jersey

New York

California

New York

New York

Aragon Pharmaceuticals Portfolio Exits

1 Portfolio Exit

Aragon Pharmaceuticals has 1 portfolio exit. Their latest portfolio exit was Seragon Pharmaceuticals on July 02, 2014.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/2/2014

Acquired

$99M

3

Date

7/2/2014

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

3

You May Also Like

Can-Fite BioPharma Logo
Can-Fite BioPharma

Can-Fite BioPharma is a biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.

M
Metronome Therapeutics

Metronome Therapeutics is developing oncology drugs

A
AnaMar Medical

AnaMar Medical is a company in the field of cartilage biology and associated joint diseases. The company has an project portfolio with five drugs and one biomarker in development and two biomarkers on the market.

I
Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

L
Locus Pharmaceuticals

Locus Pharmaceuticals is a privately held pharmaceutical company focused on developing small molecule therapeutic drugs to address unmet medical needs. The company's core technology is a fragment-based, computational approach, which Locus has combinated with highly integrated medicinal chemistry, crystallography and biology capabilities to create a unique drug design and development platform.

M
MuriGen

MuriGen is building a portfolio of drugs for unmet medical needs across a number of therapeutic areas including cancer, arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.